Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  GlaxoSmithKline Pharmaceuticals Limited    GLAXO   INE159A01016

End-of-day quote. End-of-day quote  - 06/18
2800 INR   +1.82%
05/28GLAXOSMITHKLINE : delivers strong Q4 performance with Revenue of 749..
AQ
04/25GLAXO : 1Q Earnings Snapshot
AQ
03/28Company strikes £9.2 billion deal
AQ
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   End-of-day quote. End-of-day quote National Stock Exchange O…
06/12/2018 06/13/2018 06/14/2018 06/15/2018 06/18/2018 Date
2705(c) 2825(c) 2760(c) 2750(c) 2800(c) Last
17 113 59 754 33 468 25 287 22 532 Volume
+1.69% +4.44% -2.30% -0.36% +1.82% Change
More quotes
Financials (INR)
Sales 2019 33 435 M
EBIT 2019 6 045 M
Net income 2019 4 354 M
Finance 2019 7 826 M
Yield 2019 1,73%
Sales 2020 37 281 M
EBIT 2020 7 237 M
Net income 2020 5 129 M
Debt 2020 -
Yield 2020 1,93%
P/E ratio 2019 51,75
P/E ratio 2020 43,86
Capi. / Sales2019 6,73x
Capi. / Sales2020 6,24x
Capitalization 233 B
More Financials
Company
GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals.The company's product portfolio includes prescription medicines and vaccines.Its prescription medicines range across therapeutic areas such as anti-infective, dermatology,... 
More about the company
Surperformance© ratings of GlaxoSmithKline Pharmaceut
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE PHARMACEUT
06/15ViiV Healthcare`s two-drug HIV regimen successful in late-stage studies; Glax..
AQ
06/15Glaxo Pops But Analysts Say It`s Unlikely To Swipe Gilead Share In HIV
AQ
06/13GLAXOSMITHKLINE : head of vaccines business to leave by year-end
AQ
06/07GLAXOSMITHKLINE : boosted Shingrix educational efforts after seeing administrati..
AQ
05/30INNOVIVA : Glaxo makes new drug application in Japan for COPD treatment, Trelegy..
AQ
05/28GLAXOSMITHKLINE PHARMACEUTICALS : delivers strong Q4 performance with Revenue of..
AQ
05/25GLAXOSMITHKLINE PHARMA LTD'S Q4FY18 : In-line with Estimates
AQ
05/25GLAXOSMITHKLINE PHARMACEUTICALS : PHARMA Q4 NET DIPS 6% TO Rs105 CRORE
AQ
04/25GLAXO : 1Q Earnings Snapshot
AQ
03/30FE 1000 : Rankings by market cap - glaxosmithkline pharmaceuticals lim..
AQ
More news
Sector news : Pharmaceuticals - NEC
06/18How U.S. tax reform rewards companies that shift profit to tax havens
RE
06/18Evotec Shares Jump After It Secures Sanofi Agreement
DJ
06/18Indivior shares rise after U.S. court order blocks generic rival drug
RE
06/18INDIVIOR : Wins Legal Battle; Temporarily Blocks Launch of Generic Drug
DJ
06/18SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
04/05God bless Deepak Parekh who has managed to shield the HDFC twins from Govt. s..
8
03/13HDFC AMC, the mutual fund arm of Deepak Parekh promoted HDFC will soon make i..
1
02/21Thanks for a great lunch at the iconic Birla House, adjoining Gandhi Smriti. ..
1263
02/20#NPAs Will Increase Due To #PNBFraud Case: Deepak Parekh :  
02/19'Need more regular audits in banks to ensure frauds are detected,' says HDFC ..
9
More tweets
Qtime:40
Chart GLAXOSMITHKLINE PHARMACEUT
Duration : Period :
GlaxoSmithKline Pharmaceut Technical Analysis Chart | GLAXO | INE159A01016 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE PHARMACEUT
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 2 273  INR
Spread / Average Target -17%
EPS Revisions
Managers
NameTitle
Annaswamy Vaidheesh Managing Director & Executive Director
Deepak Shantilal Parekh Non-Executive Chairman
Puja Thakur Chief Financial Officer
Raju Krishnaswamy Executive Director & Technical Director
Vrishali Desai Vice President-Medical & Clinical Research
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED10.00%3 421
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 446
ROCHE HOLDING LTD.-14.06%183 969
MERCK AND COMPANY10.24%166 880